Rein Therapeutics’ (RNTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Rein Therapeutics (NASDAQ:RNTX – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright also issued estimates for Rein Therapeutics’ Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.48) EPS, FY2028 earnings at ($0.64) EPS, FY2029 earnings at ($0.56) EPS and FY2030 earnings at $0.36 EPS.

Separately, Weiss Ratings downgraded Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Rein Therapeutics has an average rating of “Hold” and an average price target of $6.00.

View Our Latest Stock Report on Rein Therapeutics

Rein Therapeutics Trading Down 8.9%

RNTX stock opened at $0.34 on Wednesday. The company’s 50 day simple moving average is $0.66 and its 200-day simple moving average is $0.98. Rein Therapeutics has a 12 month low of $0.28 and a 12 month high of $2.10.

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.04. As a group, analysts predict that Rein Therapeutics will post -0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Rein Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Velan Capital Investment Management LP purchased a new stake in shares of Rein Therapeutics during the 2nd quarter worth about $1,768,000. Texas Capital Bank Wealth Management Services Inc boosted its stake in shares of Rein Therapeutics by 19.9% in the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 360,758 shares of the company’s stock valued at $290,000 after purchasing an additional 60,000 shares during the period. Sequoia Financial Advisors LLC acquired a new stake in Rein Therapeutics during the 2nd quarter valued at $260,000. Rock Creek Group LLC grew its holdings in Rein Therapeutics by 40.0% during the 3rd quarter. Rock Creek Group LLC now owns 175,000 shares of the company’s stock valued at $141,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Rein Therapeutics during the 3rd quarter valued at $127,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.

About Rein Therapeutics

(Get Free Report)

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious pulmonary and fibrotic diseases. Its research focuses on therapies intended to address disease processes involved in lung injury and fibrosis. The company’s pipeline includes LTI-03, an investigational candidate being developed for idiopathic pulmonary fibrosis, and LTI-01, a candidate studied for loculated pleural effusions. These programs are investigational; they are not approved treatments.

Further Reading

Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.